10/24/2008

Epix Pharmaceuticals has announced plans to slash its work force by 23% and reduce its research and development focus in order to cut costs. The contrast-agent developer said it will concentrate on developing PRX-03140 for Alzheimer's disease and PRX-08066 for chronic obstructive pulmonary disease but will continue plans to market its Vasovist MRI contrast agent.

Related Summaries